Evidence map›Paper›PMID 21206136›Full record

Trial reportEndocrine journal2011

Sitagliptin reduces albuminuria in patients with type 2 diabetes.

Sachiko Hattori

5 registry-linked trialsAbstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Endocrine journal, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 5 registered trials, which are not on this map. Cited by 62 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed, 3 pooled it
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01847313 phase3completedstarted 2013, after this paper: background citation

Phase 3 Study of the Effect of Glucagon-like-peptide 1 (GLP-1) Receptor Agonism on Renal Outcomes in Humans With Diabetic Kidney Disease

Ran2013Enrolled20Registered outcomes6Posted comparisons0ConditionsDiabetic Kidney DiseaseArmsliraglutide
PMID 20622169PMID 20002084PMID 22691169PMID 21744074PMID 22969168PMID 14675042PMID 15664230PMID 16177002PMID 16231067PMID 16374426PMID 17167242PMID 17631861other papers from this trial
Open the trial in the graph
NCT01991197 phase2completednot on this mapstarted 2014, after this paper: background citation

Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.

TypeinterventionalSponsorUniversity College DublinRan2014 to 2016Enrolled20ConditionsPsoriasis, Type 2 Diabetes MellitusArmsSitagliptin, Gliclazide, Sitagliptin matched placebo, Gliclazide matched placebo capsule
NCT02150707 completednot on this mapstarted 2014, after this paper: background citation

The Differential Effects of Diabetes Therapy on Inflammation

TypeobservationalSponsorUniversity College DublinRan2014 to 2015Enrolled17ConditionsDiabetic Nephropathy, Type 2 DiabetesArmsDipeptidyl-Peptidase IV Inhibitors, Glucagon-Like Peptide 1
NCT02347501 phase2completednot on this mapstarted 2013, after this paper: background citation

Dipeptidyl Peptidase-4 Inhibition and Narrow-band Ultraviolet-B Light in Psoriasis (DINUP): A Randomised Clinical Trial

TypeinterventionalSponsorUniversity College DublinRan2013 to 2016Enrolled118ConditionsPsoriasisArmsSitagliptin (Januvia)
NCT02462369 phase4unknown statusnot on this mapstarted 2015, after this paper: background citation

The Effects of Saxagliptin 5mg, Once Daily for 52 Weeks on 24 Hour Urine Albumin Creatinine Rate(ACR) , in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycaemic Control on Metformin or/and Acarbose

TypeinterventionalSponsorThe Second Hospital of Nanjing Medical UniversityRan2015 to 2017Enrolled88ConditionsMicroalbuminuria, Microalbuminuria /Creatinine Ratios ACRArmsSaxagliptin, glimepiride
3 · Its place in the literature

Who cites it

62 citing papers in PubMed, 3 syntheses or guidelines pooled it, 143 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Renoprotective Effects of DPP-4 Inhibitors.Antioxidants (Basel, Switzerland) · 2021
    Review
  17. Effect of sitagliptin on proteinuria in patients with type 2 diabetes - A renoprotective effect of sitagliptin.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2021
    Article
  18. Review
  19. Inflammatory Targets in Diabetic Nephropathy.Journal of clinical medicine · 2020
    Review
  20. Review

2 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Sachiko HattoriEndocrinology and Metabolism, Tsunemi-cho Clinic, Ashikaga, Tochigi, Japan. sachikohat@hb.tp1.jp

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We investigated the inhibitory effect of sitagliptin on albuminuria in patients with type 2 diabetes. Thirty-six patients (19 men and 17 women) whose HbA1c was higher than 6.5% (NGSP) despite receiving education on diet and exercise and medical treatment for at least 6 months at our clinic were enrolled into this study and were successfully followed over 6 months of sitagliptin treatment. Sitagliptin (50 mg/day) treatment significantly lowered both systolic and diastolic blood pressures, fasting blood glucose and postprandial blood glucose, HbA1c, and glycated albumin at 3 months and 6 months. Significant reductions in highly sensitive C-reactive protein and soluble vascular cell adhesion molecule 1 were also observed at 6 months. Urinary albumin excretion (measured as urinary albumin-to-creatinine ratio (ACR: mg/g Cr)) did not change in the 6 months before sitagliptin treatment (ΔACR: 2.3 ± 19.9) and decreased in the 6 months after sitagliptin treatment (ΔACR: -20.6 ± 24.6); these differences were statistically significant. At 6 months, the ACR decreased from 11.6 ± 8.4 to 4.5 ± 5.0 in 13 patients with normoalbuminuria (ACR < 30), from 98.4 ± 79 to 24.9 ± 20 in 15 patients with microalbuminuria (30 < ACR < 300), and from 1263 ± 492 to 561 ± 89 in 8 patients with macroalbuminuria (ACR > 300). Thus, the present findings strongly suggest that sitagliptin reduces albuminuria without lowering the estimated glomerular filtration rate, most likely depending on known factors such as blood sugar reduction, blood pressure reduction, and inflammation reduction, as well as yet undetermined factors caused by an increase in active glucagon-like peptide-1.

Indexed as

AlbuminuriaAnti-Inflammatory AgentsBlood PressureC-Reactive ProteinCreatinineDiabetes Mellitus, Type 2Dipeptidyl-Peptidase IV InhibitorsFemaleGlomerular Filtration RateHumansHypoglycemic AgentsMaleMiddle AgedPyrazinesSitagliptin PhosphateTriazolesAnti-Inflammatory AgentsC-Reactive ProteinCreatinineDipeptidyl-Peptidase IV InhibitorsHypoglycemic AgentsPyrazinesSitagliptin PhosphateTriazoles

Identifiers

PMID21206136
OpenAlexW1557233532

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.